Cardioprotective and Antianginal Efficacy of Nicorandil: A Comprehensive Review

尼可地尔 医学 心脏病学 药理学
作者
Harsh Goel,Matthew Carey,Abdelsalam Elshaikh,Matthew Krinock,Deepak Goyal,Sunil Nadar
出处
期刊:Journal of Cardiovascular Pharmacology [Ovid Technologies (Wolters Kluwer)]
被引量:4
标识
DOI:10.1097/fjc.0000000000001436
摘要

Abstract Angina pectoris remains a significant burden despite advances in medical therapy and coronary revascularization. Many patients (up to 30%) with angina have normal coronary arteries, with coronary microvascular disease (CMD) and/or coronary artery vasospasm (CAVS) being major drivers of the myocardial demand-supply mismatch. Even among patients revascularized for symptomatic epicardial coronary stenosis, recurrent angina remains highly prevalent. Medical therapy for angina currently centers around two disparate goals, viz secondary prevention of hard clinical outcomes and symptom control. Vasodilators such as nitrates have been first-line anti-anginal agents for decades, along with beta-blockers and calcium channel blockers. However, efficacy in terms of symptoms control is heterogenous, depending on underlying mechanism(s) of angina in an individual patient, often necessitating multiple agents. Nicorandil (NCO) is an anti-anginal first discovered in the late 1970s with a uniquely dual mechanism of action. Like a typical nitrate, it mediates medium-large vessel vasodilation via nitric oxide. Additionally, NCO has ATP-dependent potassium channel-agonist activity (K ATP ), mediating microvascular dilatation. Hence, it has proven effective in both CAVS and CMD, typically challenging patient populations. Moreover, emerging evidence suggests cardiomyocyte protection against ischemia via ischemic preconditioning (IPC) may be mediated via K ATP -agonism. Finally, there is now fairly firm evidence in favor of NCO in terms of hard event reduction among patients with stable coronary artery disease (CAD), following myocardial infarction, and perhaps even among patients with congestive heart failure (CHF). This review aims to summarize the mechanism of action of NCO, its efficacy as an anti-anginal, and current evidence behind its impact on hard outcomes. Finally, we review other cardiac and emerging non-cardiac indications for NCO use.Keywords: angina, stable ischemic heart disease, anti-anginal, efficacy, cardioprotective
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
朴素的狗完成签到,获得积分10
10秒前
稳了完成签到 ,获得积分10
10秒前
11秒前
Active完成签到,获得积分10
17秒前
haha完成签到,获得积分10
18秒前
似宁发布了新的文献求助10
18秒前
芥末完成签到,获得积分10
18秒前
幸福快乐的研究生毕业给幸福快乐的研究生毕业的求助进行了留言
20秒前
快乐完成签到 ,获得积分10
22秒前
赘婿应助似宁采纳,获得10
23秒前
NexusExplorer应助芥末采纳,获得10
23秒前
26秒前
聪明听露给聪明听露的求助进行了留言
28秒前
李子维完成签到 ,获得积分10
29秒前
小芋头关注了科研通微信公众号
30秒前
30秒前
maox1aoxin应助55555采纳,获得30
32秒前
zhi完成签到,获得积分10
33秒前
fire完成签到 ,获得积分10
33秒前
34秒前
Ericker发布了新的文献求助10
37秒前
syy发布了新的文献求助10
41秒前
皮妈完成签到 ,获得积分10
42秒前
科研通AI2S应助尔雅采纳,获得10
44秒前
冰墨完成签到,获得积分10
52秒前
54秒前
子车谷波完成签到,获得积分20
54秒前
56秒前
李麟发布了新的文献求助10
57秒前
youchgg完成签到,获得积分10
58秒前
XaiverX完成签到,获得积分10
58秒前
1分钟前
柒月完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
聪明听露关注了科研通微信公众号
1分钟前
暴躁的问兰完成签到 ,获得积分10
1分钟前
cathylll完成签到 ,获得积分0
1分钟前
高分求助中
Effect of reactor temperature on FCC yield 1500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Uncertainty Quantification: Theory, Implementation, and Applications, Second Edition 800
The Healthy Socialist Life in Maoist China 600
The Vladimirov Diaries [by Peter Vladimirov] 600
Production Logging: Theoretical and Interpretive Elements 555
Mesopotamian Divination Texts: Conversing with the Gods 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3278872
求助须知:如何正确求助?哪些是违规求助? 2917213
关于积分的说明 8385357
捐赠科研通 2588070
什么是DOI,文献DOI怎么找? 1409968
科研通“疑难数据库(出版商)”最低求助积分说明 657549
邀请新用户注册赠送积分活动 638639